Edgar Filing: Golumbeski George - Form 4

1 . .

Form 4	C									
March 01, 2	ЛЛ	~~.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		PPROVAL			
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						N OMB Number:	3235-0287		
Check t if no los subject Section Form 4	nger to STATEN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires:January 31 2005Estimated average burden hours per response0.5		
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940										
(Print or Type	e Responses)									
Golumbeski George Symb ENA			nbol	NTA PHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O ENAN PHARMA ARSENAI	NTA CEUTICALS, IN	(Mc 02/	Date of Earliest Tr onth/Day/Year) 28/2019	ansaction		X Director Officer (gi below)		% Owner her (specify		
			f Amendment, Da d(Month/Day/Year	Amendment, Date Original Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)	Table I Non F	Dominating Same	witing A o	Person	of on Donoficio	lly Owned		
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securities		equired, Disposed 5. Amount of	6. Ownership	7. Nature of		
Security (Month/Day/Year) Execution Date, if (Instr. 3) any (Month/Day/Year)		e, if Transaction Code ear) (Instr. 8)	TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or			Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect			
Reminder: Re	eport on a separate line	e for each class o	Code V f securities benef		Price	(Instr. 3 and 4)				
						5				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Reporting Owners

Edgar Filing: Golumbeski George - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Transaction Date 3A. Deemed 4. Aonth/Day/Year) Execution Date, if Transact any Code (Month/Day/Year) (Instr. 8)		onof Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Dei Sec (In:
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 102.54	02/28/2019		A	5,000		<u>(1)</u>	02/28/2029	Common Stock	5,000	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Golumbeski George C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02472	Х					
Signatures						
/s/ Nathaniel S. Gardiner as attorney-in-fact	03/01/2	2019				
**Signature of Reporting Person	Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant
 (1) (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.